Published in Clin Cancer Res on December 01, 2006
Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res (2009) 1.88
Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des (2008) 1.82
BTS statement on malignant mesothelioma in the UK, 2007. Thorax (2007) 1.51
Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Mol Cancer Ther (2009) 1.37
Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer (2008) 1.36
Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. Curr Mol Med (2010) 1.21
Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat (2013) 1.13
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs (2012) 1.12
Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer (2012) 1.06
Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase. Br J Cancer (2011) 1.05
Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells. Sci Signal (2014) 1.01
Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis (2012) 1.00
The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma. Drug Target Insights (2007) 0.96
The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines. Biochem Biophys Res Commun (2010) 0.92
Arginine dependence of tumor cells: targeting a chink in cancer's armor. Oncogene (2016) 0.86
The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells. Mol Cancer Ther (2012) 0.85
TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation. Mol Cell Biochem (2012) 0.85
Arginine deprivation and autophagic cell death in cancer. Proc Natl Acad Sci U S A (2014) 0.84
A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas. Cell Death Dis (2016) 0.83
RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cells. J Biomed Sci (2011) 0.82
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Rev Respir Med (2015) 0.81
Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy. BMC Cancer (2014) 0.79
Arginine deprivation therapy for malignant melanoma. Clin Pharmacol (2012) 0.78
BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma. Oncotarget (2016) 0.78
Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma. PLoS One (2016) 0.76
Arginine Metabolism in Bacterial Pathogenesis and Cancer Therapy. Int J Mol Sci (2016) 0.76
Single amino acid arginine deprivation triggers prosurvival autophagic response in ovarian carcinoma SKOV3. Biomed Res Int (2014) 0.76
Deprivation of L-Arginine Induces Oxidative Stress Mediated Apoptosis in Leishmania donovani Promastigotes: Contribution of the Polyamine Pathway. PLoS Negl Trop Dis (2016) 0.76
Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy. J Cancer Res Clin Oncol (2014) 0.76
Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas. J Pathol Clin Res (2014) 0.76
Co-application of canavanine and irradiation uncouples anticancer potential of arginine deprivation from citrulline availability. Oncotarget (2016) 0.75
Expression profile and down-regulation of argininosuccinate synthetase in hepatocellular carcinoma in a transgenic mouse model. J Biomed Sci (2015) 0.75
Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1. Cell Rep (2016) 0.75
Mesothelioma treatment: Are we on target? A review. J Adv Res (2014) 0.75
Proteome Differences in Placenta and Endometrium between Normal and Intrauterine Growth Restricted Pig Fetuses. PLoS One (2015) 0.75
Therapeutic arginine starvation in ASS1-deficient cancers inhibits the Warburg effect. Mol Cell Oncol (2017) 0.75
Novel systemic therapy against malignant pleural mesothelioma. Transl Lung Cancer Res (2017) 0.75
Metabolomic Profiling of the Synergistic Effects of Melittin in Combination with Cisplatin on Ovarian Cancer Cells. Metabolites (2017) 0.75
DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell (2006) 9.47
Follicular lymphoma international prognostic index. Blood (2004) 7.20
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med (2015) 5.44
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol (2012) 5.16
"Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med (2008) 4.38
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood (2004) 4.05
Small-cell lung cancer. Lancet (2011) 3.61
Imprinting on distal chromosome 7 in the placenta involves repressive histone methylation independent of DNA methylation. Nat Genet (2004) 3.47
Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res (2011) 2.85
Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol (2005) 2.81
Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res (2002) 2.71
Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol (2006) 2.67
Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst (2007) 2.65
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell (2003) 2.65
Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol (2004) 2.64
Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature (2007) 2.54
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging (2010) 2.48
The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest (2009) 2.42
iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet (2003) 2.41
Tazarotene-induced gene 1 (TIG1) expression in prostate carcinomas and its relationship to tumorigenicity. J Natl Cancer Inst (2002) 2.41
Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis (2004) 2.35
Endothelins induce CCR7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1. Cancer Res (2006) 2.30
Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci (2003) 2.29
Chinese herbal uropathy and nephropathy. Lancet (2006) 2.27
iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet (2006) 2.20
Conservation of the H19 noncoding RNA and H19-IGF2 imprinting mechanism in therians. Nat Genet (2008) 2.20
The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol (2007) 2.13
A general relationship between disorder, aggregation and charge transport in conjugated polymers. Nat Mater (2013) 2.11
Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer (2006) 2.09
Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol (2013) 2.08
Electron-pinned defect-dipoles for high-performance colossal permittivity materials. Nat Mater (2013) 2.05
Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol (2003) 2.03
Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Am J Respir Cell Mol Biol (2008) 1.99
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
The p53 pathway in breast cancer. Breast Cancer Res (2002) 1.94
Performance of anal cytology in a clinical setting when measured against histology and high-resolution anoscopy findings. AIDS (2010) 1.92
Vestibular loss causes hippocampal atrophy and impaired spatial memory in humans. Brain (2005) 1.92
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell (2008) 1.90
Adaptation of nutrient supply to fetal demand in the mouse involves interaction between the Igf2 gene and placental transporter systems. Proc Natl Acad Sci U S A (2005) 1.90
ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol (2004) 1.88
Ten years of dengue drug discovery: progress and prospects. Antiviral Res (2013) 1.84
Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol (2005) 1.83
Fluorescence lifetime imaging system for in vivo studies. Mol Imaging (2007) 1.83
A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res (2003) 1.78
MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer (2010) 1.74
Information chaos in primary care: implications for physician performance and patient safety. J Am Board Fam Med (2011) 1.72
Interaction between a G-patch protein and a spliceosomal DEXD/H-box ATPase that is critical for splicing. Mol Cell Biol (2004) 1.70
Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol (2004) 1.70
Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Mol Cancer Ther (2006) 1.69
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer (2010) 1.66
EMAGE--Edinburgh Mouse Atlas of Gene Expression: 2008 update. Nucleic Acids Res (2007) 1.66
Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene (2004) 1.64
Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes. Chest (2003) 1.64
Presentation, diagnosis, and treatment outcome of tuberculous-mediated tubulointerstitial nephritis. Kidney Int (2010) 1.64
Structural basis for nick recognition by a minimal pluripotent DNA ligase. Nat Struct Mol Biol (2007) 1.63
Left ventricular strain patterns in dilated cardiomyopathy predict response to cardiac resynchronization therapy: timing is not everything. J Am Soc Echocardiogr (2009) 1.61
B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci U S A (2011) 1.58
Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice. J Clin Invest (2011) 1.58
A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res (2011) 1.55
The bladder pain/interstitial cystitis symptom score: development, validation, and identification of a cut score. Eur Urol (2011) 1.55
Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene (2004) 1.54
Organic thin-film electronics from vitreous solution-processed rubrene hypereutectics. Nat Mater (2005) 1.53
An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol Cancer Ther (2003) 1.51
The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res (2005) 1.49
Complications following prostate needle biopsy requiring hospital admission or emergency department visits - experience from 1000 consecutive cases. BJU Int (2012) 1.48
Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol (2008) 1.46
Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One (2013) 1.45
Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther (2007) 1.44
Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol (2009) 1.40
Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog (2009) 1.39
Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol (2006) 1.39
Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor. Kidney Int (2013) 1.37
Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol (2011) 1.33
Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood (2005) 1.31
Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. J Clin Invest (2010) 1.30
Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther (2010) 1.30
The p53 network in head and neck cancer. Oral Oncol (2003) 1.30
Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol (2011) 1.30
The physiologic evaluation of patients with lung cancer being considered for resectional surgery. Chest (2003) 1.30
Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol Cancer Res (2003) 1.29
Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP). J Biol Chem (2002) 1.28
Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res (2009) 1.28
New advances in the second-line treatment of small cell lung cancer. Oncologist (2009) 1.25
Structure of the RNA 3'-phosphate cyclase-adenylate intermediate illuminates nucleotide specificity and covalent nucleotidyl transfer. Structure (2010) 1.25
Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J Clin Oncol (2006) 1.24
Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway. Oncogene (2002) 1.23
Using discrete choice experiments to estimate a preference-based measure of outcome--an application to social care for older people. J Health Econ (2006) 1.22
Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. Eur J Immunol (2002) 1.21